NCT04390646View on ClinicalTrials.gov

GnRH Therapy on Cognition in Down Syndrome

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 27, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Down SyndromeCognitive DeclineAlzheimer Disease, Early OnsetOlfaction Disorders
Interventions
DRUG

GnRH, gonadorelin acetate

Drug administered by a subcutaneous pump

DRUG

0.9% NaCl

Drug administered by a subcutaneous pump

Trial Locations (1)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors
lead

Nelly Pitteloud

OTHER